Muñoz-García Noemí, Jara-Acevedo María, Caldas Carolina, Bárcena Paloma, López Antonio, Puig Noemí, Alcoceba Miguel, Fernández Paula, Villamor Neus, Flores-Montero Juan A, Gómez Karoll, Lemes María Angelina, Hernández Jose Carlos, Álvarez-Twose Iván, Guerra Jose Luis, González Marcos, Orfao Alberto, Almeida Julia
Translational and Clinical Research Program, Centro de Investigación del Cáncer and IBMCC (CSIC-University of Salamanca), Cytometry Service, NUCLEUS, Department of Medicine, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Cancers (Basel). 2020 Nov 25;12(12):3508. doi: 10.3390/cancers12123508.
and () mutations are the most common mutations in T-cell large granular lymphocytic leukemia (T-LGLL) and chronic lymphoproliferative disorders of NK cells (CLPD-NK), but their clinical impact remains unknown. We investigated the frequency and type of mutations in FACS-sorted populations of expanded T/NK-LGL from 100 (82 clonal; 6 oligoclonal; 12 polyclonal) patients, and its relationship with disease features. Seventeen non-LGL T-CLPD patients and 628 age-matched healthy donors were analyzed as controls. ( = 30) and ( = 1) mutations were detected in 28/82 clonal T/NK-LGLL patients (34%), while absent (0/18, 0%) among oligoclonal/polyclonal LGL-lymphocytosis. Mutations were found across all diagnostic subgroups: TCD8-LGLL, 36%; CLPD-NK, 38%; TCD4-LGLL, 7%; TαβDP-LGLL, 100%; TαβDN-LGLL, 50%; Tγδ-LGLL, 44%. -mutated T-LGLL/CLPD-NK showed overall reduced ( < 0.05) blood counts of most normal leukocyte subsets, with a higher rate (vs. nonmutated LGLL) of neutropenia ( = 0.04), severe neutropenia ( = 0.02), and cases requiring treatment ( = 0.0001), together with a shorter time-to-therapy ( = 0.0001), particularly in non-Y640F mutated patients. These findings confirm and extend on previous observations about the high prevalence of mutations across different subtypes of LGLL, and its association with a more marked decrease of all major blood-cell subsets and a shortened time-to-therapy.
和()突变是T细胞大颗粒淋巴细胞白血病(T-LGLL)和自然杀伤细胞慢性淋巴细胞增殖性疾病(CLPD-NK)中最常见的突变,但它们的临床影响尚不清楚。我们调查了100例(82例克隆性;6例寡克隆性;12例多克隆性)患者经荧光激活细胞分选术(FACS)分选的扩增T/NK-LGL群体中的突变频率和类型,及其与疾病特征的关系。将17例非LGL T-CLPD患者和628例年龄匹配的健康供者作为对照进行分析。在28/82例克隆性T/NK-LGLL患者(34%)中检测到**(=30)和**(=1)突变,而在寡克隆/多克隆LGL淋巴细胞增多症患者中未检测到(0/18,0%)。在所有诊断亚组中均发现了突变:TCD8-LGLL,36%;CLPD-NK,38%;TCD4-LGLL,7%;TαβDP-LGLL,100%;TαβDN-LGLL,50%;Tγδ-LGLL,44%。突变的T-LGLL/CLPD-NK患者大多数正常白细胞亚群的血细胞计数总体降低(<0.05),与未突变的LGLL相比,中性粒细胞减少症(=0.04)、严重中性粒细胞减少症(=0.02)和需要治疗的病例(=0.0001)的发生率更高,同时治疗时间更短(=0.0001),特别是在非Y640F突变患者中。这些发现证实并扩展了先前关于LGLL不同亚型中突变高患病率及其与所有主要血细胞亚群更显著减少和治疗时间缩短相关的观察结果。